{'52WeekChange': 3.7249131,
 'SandP52WeekChange': None,
 'address1': '10628 Science Center Drive',
 'address2': 'Suite 250',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 55,
 'askSize': 900,
 'averageDailyVolume10Day': 774912,
 'averageVolume': 934060,
 'averageVolume10days': 774912,
 'beta': 3.43605,
 'beta3Year': None,
 'bid': 51.81,
 'bidSize': 1100,
 'bookValue': 1.12,
 'category': None,
 'circulatingSupply': None,
 'city': 'San Diego',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 57.4,
 'dayLow': 52.01,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -34.132,
 'enterpriseToRevenue': 53.963,
 'enterpriseValue': 1029875840,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 45.75,
 'fiftyTwoWeekHigh': 62.97,
 'fiftyTwoWeekLow': 8.51,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 13334596,
 'forwardEps': 0.32,
 'forwardPE': 167.8125,
 'fromCurrency': None,
 'fullTimeEmployees': 88,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.29925,
 'heldPercentInstitutions': 0.30923998,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1510790400,
 'lastSplitFactor': '1:7',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/arcturusrx.com',
 'longBusinessSummary': 'Arcturus Therapeutics Holdings Inc., an RNA medicines '
                        'company, focuses on the treatment of liver and '
                        'respiratory care diseases. The company engages in the '
                        'discovery and development of RNA medicines, including '
                        'the production of RNA drug substance and '
                        'nanoparticle-formulated drug product; and development '
                        'of infectious disease vaccines using its '
                        'Self-Transcribing and Replicating RNA (STARR) '
                        'technology. Its preclinical drug discovery and '
                        'development programs include LUNAR-OTC development '
                        'program that is developing mRNA compounds to treat '
                        'ornithine transcarbamylase (OTC) deficiency; LUNAR-CF '
                        'program, which is developing mRNA compounds to '
                        'replace dysfunctional cystic fibrosis transmembrane '
                        'conductance regulator (CFTR) protein in cystic '
                        'fibrosis (CF) patients; and LUNAR-CV and LUNAR-MD '
                        'that are internal research programs focused on target '
                        'validation of multiple pipeline LUNAR-mRNA program '
                        'candidates. The company owns LUNAR and nucleic acid '
                        'technologies that are covered by a patent portfolio '
                        'of 182 patents and patent applications, issued in the '
                        'United States, China, Europe, Japan, and other '
                        'countries. It has collaboration partnerships with '
                        'Ultragenyx Pharmaceutical, Inc. to develop mRNA '
                        'therapeutic candidates for certain rare disease '
                        'targets; Millennium Pharmaceuticals, Inc. (Takeda) to '
                        'develop a nucleic acid-based therapeutic candidate '
                        'for the treatment of nonalcoholic steatohepatitis; '
                        'Janssen Pharmaceuticals, Inc. to develop nucleic '
                        'acid-based therapeutic candidates for the treatment '
                        'of hepatitis B virus infection; CureVac AG; Singapore '
                        'Economic Development Board and Duke-NUS Medical '
                        'School to develop LUNAR-COV19, a vaccine to address '
                        'the Coronavirus outbreak; and Catalent, Inc. to '
                        "support the expected manufacture of Arcturus' "
                        'COVID-19 mRNA vaccine candidate (LUNAR-COV19. '
                        'Arcturus Therapeutics Holdings Inc. was founded in '
                        '2013 and is headquartered in San Diego, California.',
 'longName': 'Arcturus Therapeutics Holdings Inc.',
 'market': 'us_market',
 'marketCap': 1100436480,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_235062181',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -28884000,
 'nextFiscalYearEnd': 1640908800,
 'open': 56.03,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '858 900 2660',
 'previousClose': 54.62,
 'priceHint': 2,
 'priceToBook': 47.94643,
 'priceToSalesTrailing12Months': 57.65976,
 'profitMargins': -1.5134399,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 57.4,
 'regularMarketDayLow': 52.01,
 'regularMarketOpen': 56.03,
 'regularMarketPreviousClose': 54.62,
 'regularMarketPrice': 56.03,
 'regularMarketVolume': 646655,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 20492300,
 'sharesPercentSharesOut': 0.0953,
 'sharesShort': 1953803,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 469713,
 'shortName': 'Arcturus Therapeutics Holdings ',
 'shortPercentOfFloat': 0.1267,
 'shortRatio': 2.25,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'ARCT',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.192,
 'twoHundredDayAverage': 27.55144,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'cb9a2721-c1b9-3b25-9cc5-ea57e34e4857',
 'volume': 646655,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.arcturusrx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '92121'}